Last reviewed · How we verify
ACI-19764 at dose A6 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ACI-19764 at dose A6 (ACI-19764 at dose A6) — AC Immune SA.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ACI-19764 at dose A6 TARGET | ACI-19764 at dose A6 | AC Immune SA | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ACI-19764 at dose A6 CI watch — RSS
- ACI-19764 at dose A6 CI watch — Atom
- ACI-19764 at dose A6 CI watch — JSON
- ACI-19764 at dose A6 alone — RSS
Cite this brief
Drug Landscape (2026). ACI-19764 at dose A6 — Competitive Intelligence Brief. https://druglandscape.com/ci/aci-19764-at-dose-a6. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab